Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?

ABSTRACT:

SUBMITTER: Navar AM 

PROVIDER: S-EPMC7039320 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature